Study identifier:311CIL/0114
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multi-Centre, Open, Crossover Study, To Evaluate Preference for Either Zolmitriptan (2.5mg) Orally Dispersible Tablet Or Sumatriptan (50mg) Tablet For The Acute Treatment Of Migraine In Adult Patients.
migraine
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|